South Korea-based healthcare company Yuyu Pharma announced on Tuesday that it has completed a strategic investment in Dalan Animal Health, a US-based biotechnology company advancing an innate immunity-based platform for developing vaccines for honeybees and shrimp.
This investment will enable the company to continue to expand its platform across new species, exploring novel applications for poultry as well as other aquaculture species.
Robert Wonsang Yu, CEO of Yuyu Pharma, said: "Yuyu Pharma is moving decisively into new areas of animal health where scientific innovation can create lasting global impact. Bees, shrimp, and other essential species play foundational roles in food systems and environmental stability. Our investment in Dalan reflects a clear ambition: to engage directly with technologies that will shape the next generation of global animal health solutions."
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine